Ajanta Pharma Limited (NSE:AJANTPHARM)
India
· Delayed Price · Currency is INR | Market Cap | 322.86B |
| Revenue (ttm) | 47.43B |
| Net Income (ttm) | 9.20B |
| Shares Out | 124.89M |
| EPS (ttm) | 73.53 |
| PE Ratio | 35.16 |
| Forward PE | 31.39 |
| Dividend | 56.00 (2.07%) |
| Ex-Dividend Date | Nov 6, 2024 |
| Volume | 165,348 |
| Average Volume | 97,373 |
| Open | 2,686.10 |
| Previous Close | 2,706.10 |
| Day's Range | 2,555.80 - 2,696.50 |
| 52-Week Range | 2,111.05 - 3,485.00 |
| Beta | 0.22 |
| RSI | 45.64 |
| Earnings Date | May 2, 2025 |
About Ajanta Pharma
Ajanta Pharma Limited, a specialty pharmaceutical formulation company, together with its subsidiaries, develops, manufactures, and markets speciality pharmaceutical finished dosages. The company markets and serves various therapeutic segments, such as cardiology, antidiabetic, ophthalmology, dermatology, pain management, and respiratory areas. It also provides tablets, capsules, injectables, inhalers, ointments, creams, and liquids. The company serves in India, Africa, rest of Asia, the United States, and internationally. Ajanta Pharma Limited ... [Read more]
Financial Performance
In 2024, Ajanta Pharma's revenue was 47.43 billion, an increase of 12.69% compared to the previous year's 42.09 billion. Earnings were 9.20 billion, an increase of 12.77%.
Financial StatementsNews
Ajanta Pharma Q4 Results: Net profit grows 11% YoY to Rs 225 crore, EBITDA Margin at 25%
Ajanta Pharma Ltd. reported an 11% year-on-year increase in profit after tax (PAT) for the quarter ended March 31, 2025, at ₹225 crore, compared to ₹203 crore in the same period last year.
Stocks to buy today on brokerages’ call: IndiGo, Ajanta Pharma, TBO, HDFC Bank, Vodafone Idea among top picks – Check investment target
Several brokerage firms have issued fresh calls on select Indian stocks, highlighting investment opportunities and risks across sectors. While these are views expressed by the respective brokerage hou...
Jefferies initiates Buy on Ajanta Pharma, sees 11% upside due to strong presence in branded generics markets
Jefferies has initiated coverage on Ajanta Pharma with a ‘Buy’ call, projecting an upside of 11% from the current market price of ₹2,574.00 (as of April 11, 2025). The brokerage has set a target price...
Stocks to watch today: Interglobe Aviation, Ajanta Pharma, HDFC Bank, Vodafone Idea, Hindalco, TBO, L&T in focus on brokerage reports
A host of stocks are likely to remain in the spotlight today as several brokerages have issued fresh commentary and call actions, including upgrades, initiations, and revised target prices. Among the ...
Ajanta Pharma Q3FY25 results: Revenue rises 4% YoY to Rs 1,146 crore, PAT Up 11% to Rs 233 crore
According to IQVIA MAT December 2024 data, Ajanta Pharma’s India growth was 11%, outpacing the Indian Pharmaceutical Market (IPM) growth of 8%.
Pharma Stocks: Cipla down nearly 2%, Ajanta Pharma down 1.45%, Abbott India up 1.27%
The Nifty Pharma index was trading 0.25% lower at 22,389.10 during today’s session, as losses in Cipla, Biocon, and Aurobindo Pharma weighed on the sector, despite gains in Abbott India and Ajanta Pha...
Ajanta Pharma declares first interim dividend of ₹28 per share for FY25
Ajanta Pharma Ltd. has announced its first interim dividend for the financial year 2024-25. Each share with a face value of ₹2 will receive a dividend of ₹28, totaling an outlay of ₹350 crore. The com...
Ajanta Pharma Q2 FY25 Results: Revenue rises 15% to ₹1,187 crore, net profit grows 11% to ₹216 crore
Ajanta Pharma Ltd., a specialty pharmaceutical formulation company, has released its Q2 FY25 results, showcasing a strong performance for the quarter and half-year ending on 30th September 2024. Key H...
Pharma Stocks Update: Natco Pharma gains 2.99%, Glenmark rises 0.07%, Granules falls 3.83%
As of 2:38 PM, the Nifty Pharma index saw a mixed performance with some stocks showing notable gains while others faced losses. Natco Pharma, Glenmark, and Ajanta Pharma were the top gainers, while Gr...
Pharma Stocks Update: Granules up 3.56%, Ajanta Pharma gains 2.24% while JB Chemicals drops 2.82%, Mankind Pharma down 1.40% in mixed pharma stock performance
Pharma stocks have shown mixed performance in today’s trading session, with some major players gaining ground while others face declines. As of now, here’s how key pharmaceutical stocks are performing...